Allison Ackerman Shrier

Ackerman Shrier
President, Riptide Management

Allison Shrier, M.D., is a Research Affiliate at the MIT Center for Biomedical Innovation. Her current efforts at CBI focus on connecting and expanding novel clinical trial elements in order to develop new paradigms in drug development and nurture collaborative innovation ecosystems that can sustainably and swiftly deliver new and better therapeutics to the right patients.

Dr. Shrier brings a cross-disciplinary perspective to redesigning the drug development process globally. Trained as an oncologist, with expertise in early preclinical and clinical stage drug development and computational modeling of complex adaptive systems, she applies her capabilities to both academic and entrepreneurial pursuits. She also studies the application of novel data infrastructures to the creation of adaptive health IT ecosystems. Dr. Shrier holds degrees in Chemistry from Princeton University and Harvard University and a medical degree from Harvard Medical School, where she completed residency and fellowship training as well.